Immunomodulatory therapies for SARS-CoV-2 infection : a systematic literature review to inform EULAR points to consider
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To summarise the available information on efficacy and safety of immunomodulatory agents in SARS-CoV-2 infection.
METHODS: As part of a European League Against Rheumatism (EULAR) taskforce, a systematic literature search was conducted from January 2019 to 11 December 2020. Two reviewers independently identified eligible studies according to the Population, Intervention, Comparator and Outcome framework and extracted data on efficacy and safety of immunomodulatory agents used therapeutically in SARS-CoV-2 infection at any stage. The risk of bias was assessed with validated tools.
RESULTS: Of the 60 372 records, 401 articles were eligible for inclusion. Studies were at variable risk of bias. Randomised controlled trials (RCTs) were available for the following drugs: hydroxychloroquine (n=12), glucocorticoids (n=6), tocilizumab (n=4), convalescent plasma (n=4), interferon beta (n=2), intravenous immunoglobulins (IVIg) (n=2) and n=1 each for anakinra, baricitinib, colchicine, leflunomide, ruxolitinib, interferon kappa and vilobelimab. Glucocorticoids were able to reduce mortality in specific subsets of patients, while conflicting data were available about tocilizumab. Hydroxychloroquine was not beneficial at any disease stage, one RCT with anakinra was negative, one RCT with baricitinib+remdesivir was positive, and individual trials on some other compounds provided interesting, although preliminary, results.
CONCLUSION: Although there is emerging evidence about immunomodulatory therapies for the management of COVID-19, conclusive data are scarce with some conflicting data. Since glucocorticoids seem to improve survival in some subsets of patients, RCTs comparing glucocorticoids alone versus glucocorticoids plus anticytokine/immunomodulatory treatment are warranted. This systematic literature review informed the initiative to formulate EULAR 'points to consider' on COVID-19 pathophysiology and immunomodulatory treatment from the rheumatology perspective.
Errataetall: |
CommentIn: Ann Rheum Dis. 2021 Jun;80(6):679-681. - PMID 33658236 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
---|---|
Enthalten in: |
Annals of the rheumatic diseases - 80(2021), 6 vom: 21. Juni, Seite 803-815 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Alunno, Alessia [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.06.2022 Date Revised 02.04.2024 published: Print-Electronic CommentIn: Ann Rheum Dis. 2021 Jun;80(6):679-681. - PMID 33658236 Citation Status MEDLINE |
---|
doi: |
10.1136/annrheumdis-2020-219725 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321488393 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM321488393 | ||
003 | DE-627 | ||
005 | 20240402232510.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/annrheumdis-2020-219725 |2 doi | |
028 | 5 | 2 | |a pubmed24n1360.xml |
035 | |a (DE-627)NLM321488393 | ||
035 | |a (NLM)33589438 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Alunno, Alessia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Immunomodulatory therapies for SARS-CoV-2 infection |b a systematic literature review to inform EULAR points to consider |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.06.2022 | ||
500 | |a Date Revised 02.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a CommentIn: Ann Rheum Dis. 2021 Jun;80(6):679-681. - PMID 33658236 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVE: To summarise the available information on efficacy and safety of immunomodulatory agents in SARS-CoV-2 infection | ||
520 | |a METHODS: As part of a European League Against Rheumatism (EULAR) taskforce, a systematic literature search was conducted from January 2019 to 11 December 2020. Two reviewers independently identified eligible studies according to the Population, Intervention, Comparator and Outcome framework and extracted data on efficacy and safety of immunomodulatory agents used therapeutically in SARS-CoV-2 infection at any stage. The risk of bias was assessed with validated tools | ||
520 | |a RESULTS: Of the 60 372 records, 401 articles were eligible for inclusion. Studies were at variable risk of bias. Randomised controlled trials (RCTs) were available for the following drugs: hydroxychloroquine (n=12), glucocorticoids (n=6), tocilizumab (n=4), convalescent plasma (n=4), interferon beta (n=2), intravenous immunoglobulins (IVIg) (n=2) and n=1 each for anakinra, baricitinib, colchicine, leflunomide, ruxolitinib, interferon kappa and vilobelimab. Glucocorticoids were able to reduce mortality in specific subsets of patients, while conflicting data were available about tocilizumab. Hydroxychloroquine was not beneficial at any disease stage, one RCT with anakinra was negative, one RCT with baricitinib+remdesivir was positive, and individual trials on some other compounds provided interesting, although preliminary, results | ||
520 | |a CONCLUSION: Although there is emerging evidence about immunomodulatory therapies for the management of COVID-19, conclusive data are scarce with some conflicting data. Since glucocorticoids seem to improve survival in some subsets of patients, RCTs comparing glucocorticoids alone versus glucocorticoids plus anticytokine/immunomodulatory treatment are warranted. This systematic literature review informed the initiative to formulate EULAR 'points to consider' on COVID-19 pathophysiology and immunomodulatory treatment from the rheumatology perspective | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a immune system diseases | |
650 | 4 | |a inflammation | |
650 | 4 | |a therapeutics | |
650 | 7 | |a Glucocorticoids |2 NLM | |
650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
650 | 7 | |a Hydroxychloroquine |2 NLM | |
650 | 7 | |a 4QWG6N8QKH |2 NLM | |
700 | 1 | |a Najm, Aurélie |e verfasserin |4 aut | |
700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
700 | 1 | |a De Marco, Gabriele |e verfasserin |4 aut | |
700 | 1 | |a Emmel, Jenny |e verfasserin |4 aut | |
700 | 1 | |a Mason, Laura |e verfasserin |4 aut | |
700 | 1 | |a McGonagle, Dennis G |e verfasserin |4 aut | |
700 | 1 | |a Machado, Pedro M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 80(2021), 6 vom: 21. Juni, Seite 803-815 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
773 | 1 | 8 | |g volume:80 |g year:2021 |g number:6 |g day:21 |g month:06 |g pages:803-815 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-219725 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 80 |j 2021 |e 6 |b 21 |c 06 |h 803-815 |